SCHEDULE: Armistice Capital Discloses Stake in Sangamo Therapeutics

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 9.75% of Sangamo Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of Sangamo Therapeutics, Inc. common stock.
• The filing, dated March 31, 2026, shows a total of 40,400,067 shares owned, representing 9.75% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The filing clarifies that the Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of ownership and does not inherently signal positive or negative performance for Sangamo Therapeutics, but indicates significant investor interest.

Positives

• Significant ownership stake of 9.75% in Sangamo Therapeutics, Inc. by Armistice Capital and Steven Boyd.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The Master Fund disclaims beneficial ownership of the shares it directly holds, which could be a point of confusion.
• No voting or sole dispositive power is held by Armistice Capital or Steven Boyd directly, only shared power.

Risks

• Potential for increased scrutiny from regulators or other investors due to the significant ownership stake.
• The nature of the investment management agreement could lead to future disputes or changes in control.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant ownership disclosures like this Schedule 13G filing often precede or coincide with activist investor campaigns or strategic shifts within a company. Investors will be watching to see if Armistice Capital intends to influence Sangamo Therapeutics' corporate strategy or governance.

Stakeholder Impact

• Shareholders: May see increased volatility or strategic shifts in the company due to the significant stake held by Armistice Capital.
• Management: May face pressure or engagement from Armistice Capital regarding corporate strategy and governance.
• Creditors: Indirect impact through potential changes in company strategy that could affect financial stability.

Next Steps

• Monitor future filings from Armistice Capital for any changes in ownership or strategic actions.
• Observe Sangamo Therapeutics' response and any potential strategic or governance changes.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide performance data or strategic guidance for Sangamo Therapeutics. Therefore, a 'hold' recommendation is appropriate pending further information on Armistice Capital's intentions and the company's performance.

Keywords

Sangamo Therapeutics, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management